Dyne Therapeutics Submits Biologics License Application for Duchenne Treatment

Dyne Therapeutics (NASDAQ:DYN) submitted its Biologics License Application to the FDA for z-rostudirsen, a treatment for Duchenne muscular dystrophy. The company is seeking Priority Review status, which could reduce approval time from ten months to six and plans a commercial launch in Q1 2027.

By Muhammad Ali Khalid Fri, June 5, 2026 at 6:55 PM GMT+3 2 min read · Yahoo Finance · June 5, 2026, 15:55 UTC

Dyne Therapeutics Submits Biologics License Application for Duchenne Treatment

Tickers: $DYN

Topics: biotech drug approval duchenne muscular dystrophy

Read the full article at Yahoo Finance

More World news

Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang's Resignation CNBC · November 12, 2026, 16:59 UTC
Brookfield Corporation Reports Strong Third Quarter Earnings Growth and Increased Share Buybacks Motley Fool · November 12, 2026, 17:08 UTC
Franco-Nevada Reports Q3 2026 Revenue Growth Driven by Higher Gold and Oil Prices Motley Fool · November 12, 2026, 17:10 UTC
Stratasys Reports Q3 2026 Revenue Growth Driven by Aerospace and Defense Demand Motley Fool · November 12, 2026, 17:11 UTC
Jim Cramer Advises Profit-Taking Following Jensen Huang's Resignation at Nvidia CNBC · November 12, 2026, 16:59 UTC
LexisNexis Report Shows Elevated U.S. Auto Insurance Shopping Volumes in Q3 2026 PR Newswire · November 12, 2026, 17:12 UTC
Suburban Propane Partners Outlines $60M-$70M Capital Expenditures for Fiscal 2027 Seeking Alpha · November 12, 2026, 17:00 UTC
Nvidia, Supermicro, and Megaspeed Face U.S. Department of Justice Probes Seeking Alpha · November 12, 2026, 17:00 UTC
Starbucks Implements Quarterly Performance-Based Bonuses for Baristas Seeking Alpha · November 12, 2026, 17:03 UTC
Jim Cramer Analyzes Nvidia Leadership Transition and Recommends AMD, Constellation Brands, and Kimberly-Clark CNBC · November 12, 2026, 16:55 UTC